Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2017 2
2018 4
2019 4
2020 7
2022 1
2023 0
Text availability
Article attribute
Article type
Publication date

Search Results

14 results
Results by year
Filters applied: . Clear all
Page 1
Diroximel fumarate (DRF) in patients with relapsing-remitting multiple sclerosis: Interim safety and efficacy results from the phase 3 EVOLVE-MS-1 study.
Naismith RT, Wolinsky JS, Wundes A, LaGanke C, Arnold DL, Obradovic D, Freedman MS, Gudesblatt M, Ziemssen T, Kandinov B, Bidollari I, Lopez-Bresnahan M, Nangia N, Rezendes D, Yang L, Chen H, Liu S, Hanna J, Miller C, Leigh-Pemberton R. Naismith RT, et al. Among authors: nangia n. Mult Scler. 2020 Nov;26(13):1729-1739. doi: 10.1177/1352458519881761. Epub 2019 Nov 4. Mult Scler. 2020. PMID: 31680631 Free PMC article.
Narsoplimab, a Mannan-Binding Lectin-Associated Serine Protease-2 Inhibitor, for the Treatment of Adult Hematopoietic Stem-Cell Transplantation-Associated Thrombotic Microangiopathy.
Khaled SK, Claes K, Goh YT, Kwong YL, Leung N, Mendrek W, Nakamura R, Sathar J, Ng E, Nangia N, Whitaker S, Rambaldi A; OMS721-TMA-001 Study Group Members. Khaled SK, et al. Among authors: nangia n. J Clin Oncol. 2022 Aug 1;40(22):2447-2457. doi: 10.1200/JCO.21.02389. Epub 2022 Apr 19. J Clin Oncol. 2022. PMID: 35439028 Free PMC article. Clinical Trial.
Reply to Kunoe (2020) and Ghosh & Singh (2020) regarding Nunes et al. (2020): Opioid use and dropout from extended-release naltrexone in a controlled trial: implications for mechanism.
Nunes EV, Bisaga A, Krupitsky E, Nangia N, Silverman BL, Akerman SC, Sullivan MA. Nunes EV, et al. Among authors: nangia n. Addiction. 2020 Nov;115(11):2188-2190. doi: 10.1111/add.15153. Epub 2020 Jul 16. Addiction. 2020. PMID: 32533597 Free PMC article. No abstract available.
Outpatient transition to extended-release injectable naltrexone for patients with opioid use disorder: A phase 3 randomized trial.
Bisaga A, Mannelli P, Yu M, Nangia N, Graham CE, Tompkins DA, Kosten TR, Akerman SC, Silverman BL, Sullivan MA. Bisaga A, et al. Among authors: nangia n. Drug Alcohol Depend. 2018 Jun 1;187:171-178. doi: 10.1016/j.drugalcdep.2018.02.023. Epub 2018 Apr 10. Drug Alcohol Depend. 2018. PMID: 29674251 Free article. Clinical Trial.
14 results